Ohio University ranks fourth in nation for research return on investment

Forbes magazine has ranked Ohio University first in the state and fourth in the nation for returns on research investment, largely due to OU-COM research. The university earned $9.3 million in licensing royalties in the past two years for the acromegaly drug Somavert^®, which developed out of a 1988 research discovery by John Kopchick, Ph.D., Goll-Ohio Eminent Scholar and professor of molecular biology.

The Forbes study was based on 2006 data from the Association of University Technology Managers. Income generated by Somavert^® is reinvested in research at all levels of the university.